Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease

Inovio Pharmaceuticals Inc INO announced interim results from an ongoing Phase 1/2 trial evaluating INO-3107 for HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.
RRP is caused primarily by HPV types 6 and/or 11 characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract.
In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth.
INO-3107 was also observed to be well-tolerated and immunogenic in the trial.
In the trial, treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing CD4 and CD8 T cells. All 21 participants demonstrated an increase in peripheral T cells to one or more antigens in INO-3107 post-baseline.
T-cell responses against HPV 6 and HPV 11 were also still observed at Week 52, 43 weeks after treatment with INO-3107, indicating a persistent cellular memory response.
INO-3107 was well-tolerated, with all participants completing the trial follow-up.
Results from the second cohort of 11 patients are expected in the first half of 2023.
Price Action: INO shares are down 5.21% at $1.55 on the last check Thursday.